{"version":"1.0","provider_name":"Avalere Health Advisory","provider_url":"https:\/\/advisory.avalerehealth.com","title":"FDA Restrictions on PD-L1-Negative Gastric Cancer Treatments | Avalere Health Advisory","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"OsJdbiCs5v\"><a href=\"https:\/\/advisory.avalerehealth.com\/insights\/fda-restrictions-on-pd-l1-negative-gastric-cancer-treatments\">FDA Restrictions on PD-L1-Negative Gastric Cancer Treatments<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/advisory.avalerehealth.com\/insights\/fda-restrictions-on-pd-l1-negative-gastric-cancer-treatments\/embed#?secret=OsJdbiCs5v\" width=\"600\" height=\"338\" title=\"&#8220;FDA Restrictions on PD-L1-Negative Gastric Cancer Treatments&#8221; &#8212; Avalere Health Advisory\" data-secret=\"OsJdbiCs5v\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n<\/script>\n","thumbnail_url":"https:\/\/advisory.avalerehealth.com\/wp-content\/uploads\/2022\/10\/24304-1-JessicaCortez-400x600-1.jpg","thumbnail_width":600,"thumbnail_height":400,"description":"In June 2025, the US Food and Drug Administration (FDA) revised the labels for Merck\u2019s Keytruda (pembrolizumab) and Bristol Myers Squibb\u2019s Opdivo (nivolumab), limiting their use in advanced gastric, gastroesophageal junction (GEJ) and esophageal cancers to patients whose tumors express programmed cell death ligand 1 (PD-L1) with combined positive score \u2265 1 as determined by&hellip;"}